Aussie Alchemia Forms Audeo Oncology For Cancer Drug Business
This article was originally published in PharmAsia News
Executive Summary
Australian biotech Alchemia plans to split its cancer-drug business into a new company Audeo Oncology, while the parent concentrates on its generic of GlaxoSmithKline's Arixta (fondaparinux) anti-coagulant.